Metformin Does Not Improve Survival in High-Risk Breast Cancer
MONDAY, June 6, 2022 -- For patients with high-risk nonmetastatic breast cancer receiving standard therapy, the addition of metformin does not improve invasive disease-free survival, according to a study published in the May 24/31 issue of the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 6, 2022 Category: Pharmaceuticals Source Type: news
Early Metformin Minimizes Antipsychotic-Induced Weight Gain Early Metformin Minimizes Antipsychotic-Induced Weight Gain
A new guideline provides a protocol for the use of metformin, an inexpensive drug that has the most evidence for efficacy against antipsychotic-induced weight gain.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - June 1, 2022 Category: Psychiatry Tags: Psychiatry News Source Type: news
Metformin, Lifestyle Changes Cut Risk for T2DM, But Not CVD
FRIDAY, May 27, 2022 -- Neither lifestyle intervention nor metformin reduced major cardiovascular events in adults with prediabetes during the 21-year Diabetes Prevention Program Outcomes Study (DPPOS), according to research published online May 23... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 27, 2022 Category: Pharmaceuticals Source Type: news
Diabetes Drug Metformin Disappoints in New Breast Cancer Treatment Trial
Title: Diabetes Drug Metformin Disappoints in New Breast Cancer Treatment TrialCategory: Health NewsCreated: 5/26/2022 12:00:00 AMLast Editorial Review: 5/26/2022 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - May 26, 2022 Category: Cancer & Oncology Source Type: news
Metformin Bombs in Breast Cancer in Landmark Trial Metformin Bombs in Breast Cancer in Landmark Trial
The largest trial to date investigating the diabetes drug metformin in cancer found no survival benefit for patients with most common types of breast cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 25, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
No Cardioprotection Seen With Long-Term Metformin or Lifestyle Intervention
(MedPage Today) -- Certain interventions didn't help to keep cardiovascular (CV) events at bay among those with prediabetes, even when long-term diabetes prevention strategies were in place, according to the Diabetes Prevention Program (DPP) Outcomes... (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - May 24, 2022 Category: Primary Care Source Type: news
SGLT-2 inhibitors as First-Line Therapy in Type 2 Diabetes? SGLT-2 inhibitors as First-Line Therapy in Type 2 Diabetes?
Real-world study finds heart failure hospitalization reduction compared to metformin but not MI, stroke, or overall mortality, and greater genital infection risk.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 23, 2022 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
SGLT2 Inhibitors a Better First Drug in Type 2 Diabetes Than Metformin?
(MedPage Today) -- Using SGLT2 inhibitors in the first-line treatment of type 2 diabetes lowered some cardiovascular risk, a claims database study showed.
The combined 12-month risk for myocardial infarction (MI), stroke, and death was similar... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 23, 2022 Category: Cardiology Source Type: news
Metformin and the Risk of Prostate Cancer in Diabetic Men Metformin and the Risk of Prostate Cancer in Diabetic Men
This study aimed to clarify apparent conflicting evidence of prior studies.American Journal of Epidemiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 5, 2022 Category: Consumer Health News Tags: Public Health & Prevention Journal Article Source Type: news
Metformin Use Likely Reduces Alzheimer's Disease Risk Metformin Use Likely Reduces Alzheimer's Disease Risk
Investigating the causal effect of the drug ' s potential risk reduction.First Look (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - April 21, 2022 Category: Psychiatry Tags: Neurology & Neurosurgery News Source Type: news
Dementia: Metformin could reduce risk of the brain condition - symptoms
DEMENTIA is an umbrella term for a group of neurodegenerative diseases. Around the UK thousands of people and families suffer from a condition for which there are no effective treatments to reverse the brain disease. A new study suggests the diabetes drug metformin could reduce the risk of the disease in the first place. (Source: Daily Express - Health)
Source: Daily Express - Health - April 19, 2022 Category: Consumer Health News Source Type: news
Meta-Analysis Confirms Neuroprotective Benefit of Metformin Meta-Analysis Confirms Neuroprotective Benefit of Metformin
Metformin was associated with a reduced risk of neurodegenerative disease in a meta-analysis of 12 studies. The size of the neuroprotective effect increased with duration of use.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 18, 2022 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Better Survival in Older Cancer Patients Who Also Take Metformin Better Survival in Older Cancer Patients Who Also Take Metformin
Older patients with advanced cancer who also had diabetes and were taking metformin were found to have better survival than those not taking metformin.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 12, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Does Metformin Blunt Diabetes Link to Brain Aging? Does Metformin Blunt Diabetes Link to Brain Aging?
Study involved neurocognitive evaluation and compared data to age-matched healthy controls.First Look (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - April 11, 2022 Category: Psychiatry Tags: Diabetes & Endocrinology News Source Type: news
PARP Inhibitor-Based Triplet Promising in Endometrial Cancer
(MedPage Today) -- NEW ORLEANS -- A triplet combination of the PARP inhibitor olaparib (Lynparza), metronomic cyclophosphamide, and metformin was feasible and showed encouraging efficacy in elderly, heavily pretreated patients with recurrent... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 11, 2022 Category: Hematology Source Type: news
